Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Human anti-human tigit antibody and its application

An antibody and single-chain antibody technology, applied in the field of biomedicine, can solve the problems of limited benefited patients, poor tumor effect, and unclear reasons, and achieve the effect of enhancing killing activity, superior killing activity, and promoting killing activity.

Active Publication Date: 2021-11-16
ACADEMY OF MILITARY MEDICAL SCI
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At the same time, the in-depth exploration of clinical practice has gradually revealed the outstanding problems faced by the first generation of immune checkpoint antibodies: limited benefit patients, poor effect of most tumors, drug resistance, etc.
As mentioned above (1) (2), the regulatory functions of TIGIT on immune effector cells and Treg cells are completely opposite (inhibition and promotion), and the reason is not clear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human anti-human tigit antibody and its application
  • Human anti-human tigit antibody and its application
  • Human anti-human tigit antibody and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0121] Embodiment 1, the generation of human source anti-human TIGIT antibody

[0122] 1. Materials

[0123] 1. Materials: The large-capacity fully synthetic phage single-chain antibody library was constructed by the Institute of Bioengineering of the former Academy of Military Medical Sciences (now the Academy of Military Medical Sciences) of the Chinese People's Liberation Army (ZL200910091261.8), with a library capacity of 1.35×10 10 . The host strain for phage infection was XL1-Blue (Stratagene, USA), the plasmid amplification strain was Top10 (Beijing Quanshijin Biotechnology Co., Ltd.), the helper phage was M13KO7 (Invitrogene, USA), horseradish catalase (HRP )-labeled anti-M13KO7 antibody (11973-MM05T-H) is a product of Beijing Sino Biological Technology Co., Ltd. CHO cells and TransIntro EL Transfection Reagent (L20313) were purchased from Beijing Quanshijin Biotechnology Co., Ltd. Opti-MEM serum-free medium for transfection and 1640 medium for cell culture, 0.25% t...

Embodiment 2

[0149] Example 2, the binding activity of AET2010

[0150] 1. Materials and methods

[0151] 1. Materials: Anti-TIGIT monoclonal antibody MK7684 can be obtained from Merck & Co., USA, and its light and heavy chain genes can also be synthesized and cloned into pABK ( figure 1 ) and pABG vectors were prepared according to the preparation method of AET2010 in Example 1 (patent number: US20160355589A1), the light chain and heavy chain amino acid sequences of MK7684 are shown in SEQ ID NO.11 and SEQ ID NO.12 respectively, and the light chain of MK7684 The gene sequences of the heavy chain and heavy chain are respectively shown in SEQ ID NO.13 and SEQ ID NO.14, and MK7684 is used as a control antibody.

[0152] Wherein, the light chain expression vector of MK7684 is a recombinant vector obtained by replacing the recognition sequence between Xba I and Nar I of the pABK expression vector with the light chain variable region gene shown in positions 1-327 of SEQ ID NO.13, The recombin...

Embodiment 3

[0178] Example 3, the blocking activity of AET2010

[0179] 1. Materials and methods

[0180] 1. Materials: The human CD155 (HG29682-UT) cDNA cloning vector is a product of Beijing Sino Biological Technology Co., Ltd. HiTrap for protein purification TM The Q-Sepharose FF anion adsorption column was produced by GE, the FITC-labeled mouse anti-human IgG / Fc flow antibody was produced by Biolegend, and the HRP-labeled goat anti-human IgG / Fc antibody was produced by Beijing Baixinyi Biotechnology Co., Ltd. The isotype control antibody (C103S) is a product of Beijing Sino Biological Technology Co., Ltd. Other related material sources are with embodiment 1,2.

[0181] 2. Method:

[0182] 2.1 Preparation of AET2010-Fab, MK7684-Fab and CD155-Fc recombinant protein

[0183] The antibody Fab segment heavy chain expression vector is a pABG vector without CH2 and CH3 gene sequences, and its name is pABG-Fab ( figure 1 , whose sequence is SEQ ID NO.22 in the sequence listing), the he...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention discloses a human anti-human TIGIT antibody and its application. The anti-human TIGIT antibody disclosed by the present invention contains a heavy chain variable region V H and light chain variable region V L , V H and V L Both consist of determinant complementary regions and framework regions; V H and V L The determinant complementary regions are composed of CDR1, CDR2 and CDR3; V H The amino acid sequences of CDR1, CDR2 and CDR3 are shown in the 30-35th, 50-66th and 99-107th amino acids of SEQ ID No.10; V L The amino acid sequences of CDR1, CDR2 and CDR3 are shown in amino acids 23-33, 49-55 and 88-96 of SEQ ID No.9. The antibody of the invention can bind TIGIT with high affinity, can effectively block the combination of CD155 and TIGIT, and has anti-tumor activity.

Description

technical field [0001] The invention relates to the human anti-human TIGIT antibody and its application in the field of biomedicine. Background technique [0002] Cancer immunotherapy (Cancer Immunotherapy) is a frontier hot field in the basic and clinical research of tumor treatment in recent years. In 2011, the CTLA-4 inhibitor Ipilimumab (Ipilimumab, also known as "Y drug") was approved for marketing. The antibody exerts an anti-tumor effect by activating the immune response mediated by T cells; A whole new era of immunotherapy. Since 2014, PD-1 / PD-L1 antibodies such as Nivolumab (also known as "O drug") and Pembrolizumab (also known as "K drug") have been released one after another. It has achieved remarkable curative effect and profoundly changed the paradigm of cancer treatment. James Allison, an American scientist who promotes the development of CTLA-4 drugs, and Tasuku Honjo, a Japanese scientist who discovered PD-1 / PD-L1 molecules, also won the 2018 Nobel Prize f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/28C12N15/13A61K39/395A61K35/17A61P35/00
Inventor 杜鹏杨志新韩冬徐银凤岳俊杰余云舟陆建昇
Owner ACADEMY OF MILITARY MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com